Nectar Lifesciences shareholders approved key proposals at its Extraordinary General Meeting.

They approved the appointment of Dr. Surulichamy Senthilkumar as a Director and as a Whole-time Director (R&D) for three years.

Critically, shareholders also greenlit the transfer of the company's business to Ceph Lifesciences Private Limited on a 'slump sale' basis as a going concern.

This strategic move could streamline operations or unlock value for the company.

Voting results will be released separately.